CORRECTING and REPLACING Cytori Enters $27 Million Term Loan with Oxford Finance Corporation and Silicon Valley Bank

  CORRECTING and REPLACING Cytori Enters $27 Million Term Loan with Oxford
  Finance Corporation and Silicon Valley Bank

CORRECTION...by Cytori Therapeutics

Business Wire

SAN DIEGO -- July 1, 2013

Third bullet point in release should read: The interest-only payment period
may be extended by six months through January 2015 (sted The interest-only
payment period may be extended by six months to January 2014)

The corrected release reads:

CYTORI ENTERS $27 MILLION TERM LOAN WITH OXFORD FINANCE CORPORATION AND
SILICON VALLEY BANK

Cytori Therapeutics (NASDAQ: CYTX) entered into a four year, $27 million term
loan with Oxford Finance Corporation and Silicon Valley Bank. The loan
provides for an interest-only payment period of at least 12-months with the
potential to be extended up to 18-months. Proceeds were used to prepay
Cytori’s existing loan with GE Capital, Oxford Finance Corporation, and
Silicon Valley Bank. The loan was funded in full on June 28, 2013 and matures
July 1, 2017.

Select terms of the loan include the following:

  *Fixed interest rate of 9.75% compared with 9.87% for the prior loan
  *Interest-only payments for 12-months followed by 36 equal monthly
    principal and interest payments
  *The interest-only payment period may be extended by six months through
    January 2015 should Cytori achieve $27 million in 12-month trailing
    revenues for the period ending June 30, 2014
  *Cytori will issue warrants to Oxford Finance Corporation and Silicon
    Valley Bank for the right to purchase an aggregate of 596,553 shares of
    the Company’s common stock at an exercise price per share of $2.26 for
    seven years

“We worked closely with our lenders and were able to tailor a new loan that
meets our specific needs,” said Mark E. Saad, Chief Financial Officer, Cytori
Therapeutics. “The loan provides an additional $8 million to help fund our
ongoing operations, including clinical trial activities and reduces our
near-term cash obligations by approximately $8 million to coincide with
anticipated second half revenue growth.”

About Cytori

Cytori Therapeutics is developing cell therapies based on autologous
adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and
other medical conditions. Our scientific data suggest ADRCs improve blood
flow, moderate the inflammatory response and keep tissue at risk of dying
alive. As a result, we believe these cells can be applied across multiple
“ischemic” conditions. These therapies are made available to the physician and
patient at the point-of-care by Cytori’s proprietary technologies and
products, including the Celution® System product family. www.cytori.com

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking statements regarding events,
trends and business prospects, which may affect our future operating results
and financial position. Such statements including those regarding our expected
second half revenue growth are all subject to risks and uncertainties that
could cause our actual results and financial position to differ materially.
Some of these risks and uncertainties include, but are not limited to, risks
related to our history of operating losses, the need for further financing and
our ability to access the necessary additional capital for our business,
inherent risk and uncertainty in the protection intellectual property rights,
regulatory uncertainties, risks in the collection and results of clinical
data, final clinical outcomes, dependence on third party performance,
performance and acceptance of our products in the marketplace, as well as
other risks and uncertainties described under the heading "Risk Factors" in
Cytori's Securities and Exchange Commission Filings on Form 10-K and Form
10-Q. We assume no responsibility to update or revise any forward-looking
statements to reflect events, trends or circumstances after the date they are
made.

Contact:

Cytori Therapeutics
Investors
Tom Baker, +1-858-875-5258
tbaker@cytori.com
or
Media
Megan McCormick, +1-858-875-5279
mmccormick@cytori.com